Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash from Investing Activities (2016 - 2025)

Surgery Partners' Cash from Investing Activities history spans 12 years, with the latest figure at -$126.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 12.89% year-over-year to -$126.1 million; the TTM value through Dec 2025 reached -$246.6 million, up 49.52%, while the annual FY2025 figure was -$246.6 million, 49.52% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$126.1 million at Surgery Partners, down from -$46.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $2.1 million in Q2 2025 and bottomed at -$244.1 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is -$71.0 million (2023), against an average of -$80.0 million.
  • The largest annual shift saw Cash from Investing Activities crashed 444.71% in 2021 before it surged 100.86% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$190.0 million in 2021, then soared by 62.0% to -$72.2 million in 2022, then increased by 19.53% to -$58.1 million in 2023, then crashed by 92.25% to -$111.7 million in 2024, then decreased by 12.89% to -$126.1 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Cash from Investing Activities are -$126.1 million (Q4 2025), -$46.2 million (Q3 2025), and $2.1 million (Q2 2025).